Status:

WITHDRAWN

Vitamin D Replacement in Statin-Induced Myopathy

Lead Sponsor:

McGill University Health Centre/Research Institute of the McGill University Health Centre

Conditions:

HMG COA Reductase Inhibitor Adverse Reaction

Eligibility:

All Genders

18+ years

Phase:

NA

Brief Summary

Pretreating people with replacement doses of vitamin D will allow them to tolerate Statin medications that have caused muscle pain for them in the past.

Detailed Description

Patients who have been unable to tolerate statin medications due to muscle pain will be randomly assigned to receive vitamin D or placebo for 6 weeks before reintroducing their statin medication. The ...

Eligibility Criteria

Inclusion

  • male and female adults
  • identified by their physician as having myalgia with their statin medication.

Exclusion

  • Unexplained CK \> 4X upper limit of normal, at study entry, or on a statin medication in the past.
  • Severe myositis
  • Consumption in excess of 14 alcoholic beverages per week
  • Situations which will cause difficulty in interpreting the vitamin D and / or PTH.
  • examples:
  • Present consumption of vitamin D supplements \> 1000 iu daily
  • Renal impairment (Estimated creatinine clearance \< 70 ± 14 mL/min/m2 in Males; and \< 60 ± 10 mL/min/m2 in Females)
  • Chronic liver disease or impaired liver function
  • Any contraindication for statin re-challenge Example: rhabdomyolysis or allergy to statins

Key Trial Info

Start Date :

October 1 2010

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

July 1 2012

Estimated Enrollment :

Patients enrolled

Trial Details

Trial ID

NCT01400009

Start Date

October 1 2010

End Date

July 1 2012

Last Update

April 7 2015

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

MUHC-Royal Victoria Hospital

Montreal, Quebec, Canada, H3A 1A1